Publication - Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism

VHFC researchers at Tulane University have published findings in the Journal of Virology on an antiviral peptide with potential implications for Lassa fever (LF) treatment. Unlike ribavirin, the only drug currently used to treat LF, the peptide is not acutely toxic, and its activity is highly specific against arenaviruses.

Publication - Lassa Fever in Post-Conflict Sierra Leone

VHFC researchers publish promising results from a five-year Lassa Fever trial conducted in post-conflict Sierra Leone. The trial demonstrated the ability of a rapid diagnostic test, developed by Corgenix Medical and other members of the Consortium, to quickly detect Lassa virus.

Press Release - VHFC responds to ongoing Ebola outbreak

KENEMA, Sierra Leone – March 27, 2014 – A Viral Hemorrhagic Fever Consortium (VHFC) team is assembling in Sierra Leone to respond to the ongoing Ebola outbreak in neighboring Guinea. The Ministry of Health in Guinea has most recently reported a total of 103 suspected cases and 66 deaths mostly in the areas of southeastern Guinea.

Press Release - Corgenix expands Lassa virus rapid test research to Ebola test development

An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.

Publication - Researchers at the Scripps Research Institute make major advances in the fight against Ebola virus

Professor Erica Ollmann Saphire's group at the Scripps Research Institute in La Jolla California has published ground-breaking research into the mechanisms behind how the Ebola virus replicates and spreads.

Corgenix Gains CE Mark for ReLASV® Antigen Rapid Test for Diagnosis of Lassa Fever

VHFC partner, Corgenix Medical Corporation, has developed the first commercialized diagnostic test that enables rapid diagnosis of Lassa viral hemorrhagic fever.

"This 15-minute test has the potential to completely change stye way Lassa fever is detected and treated," said Douglas Simpson, Corgenix President.

VHFC Investigators take part in 11th Annual ASM Biodefense and Emerging Diseases Research Meeting

Scientists from Tulane and Harvard University took part in the 2013 ASM Biodefense and Emerging Diseases Research Meeting held on February 25-27 in Washington D.C. The event featured talks by Dr. Jennifer Spence (School of Medicine, Tulane University) and Dr.

Publication - Lassa fever: why there are more public health questions than answers

In an article published in The Guardian, VHFC Scientist Dr. Lina Moses discusses her research into the Mastomys rodents that transmit Lassa fever and how novel approaches to rodent control are being used to combat the disease on a local level.

The Virus Hunter - Erica Ollmann Saphire featured in U-T San Diego

A recent article in U-T San Diego features structural biologist and VHFC researcher Erica Ollmann Saphire. The article discusses her career path and research into the structures of virus-related proteins such as Lassa and Ebola.

Read full article.

Publication - A Historical Look at the First Reported Cases of Lassa Fever: IgG Antibodies 40 Years After Acute Infection.

VHFC scientists were able to locate three persons who worked in Nigeria dating back to the 1940s, two of whom were integrally involved in the early outbreaks and investigations of Lassa fever in the late 1960s, including the person from whom Lassa virus was first isolated.

Syndicate content
PSD to Drupal theme